Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.44 |
| ▸ | ALPL | P05186 | 3/20 | 0.41 |
| ▸ | ALPI | P09923 | 2/20 | 0.41 |
| ▸ | ALPG | P10696 | 2/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13133026 | 0.92 | MAPKAPK2 (0.46) | MAPKAPK2ALPLALPIALPGGRIN2D | |
| SCHEMBL2818198 | 0.89 | MCHR1 (0.40) | MAPKAPK2ALPLALPIALPG | |
| SCHEMBL2815452 | 0.87 | MAPKAPK2 (0.47) | MAPKAPK2ALPLALPIALPGGRIN2D | |
| SCHEMBL2814063 | 0.84 | MCHR1 (0.43) | MAPKAPK2ALPLALPIALPG | |
| SCHEMBL2814556 | 0.83 | ROCK2 (0.53) | — | |
| SCHEMBL2815670 | 0.82 | NTRK1 (0.40) | MAPT | |
| SCHEMBL13133029 | 0.82 | MAPKAPK2 (0.40) | MAPKAPK2ALPLALPIALPG | |
| SCHEMBL17957257 | 0.81 | MAPKAPK2 (0.44) | MAPKAPK2ALPLALPIALPGGRIN2D | |
| SCHEMBL2813215 | 0.80 | NTRK1 (0.41) | MAPT | |
| SCHEMBL17957278 | 0.79 | MCHR1 (0.38) | MAPKAPK2ALPLALPIALPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | SDHA, SDHB, TPD52L2 | MAPKAPK2 4511/4885ALPL 1707/4885ALPI 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.